As the first and only PD-L1 immune checkpoint inhibitor approved for aCSCC, UNLOXCYT is an evolution in checkpoint inhibition ...

Robot-assisted esophagectomy with extended mediastinal lymph node dissection: The learning curve and surgical outcomes. This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal Cancers ...

The FDA has approved cosibelimab-ipdl for the treatment of adults with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or radiation. The ...

Combining retifanlimab (Zynyz) with standard-of-care chemotherapy significantly improved progression-free survival (PFS) in treatment-naïve patients with locally advanced or metastatic squamous cell ...

Skin malignancies are the most common cancers in the United States. 1 Typically, skin cancer is categorized as either melanoma or non­melanoma skin cancer, which is also known as keratinocyte ...

Alcohol and tobacco use are two of the most important risk factors for head and neck cancers. However, a large portion of new head and neck diagnoses are being driven by cancer-causing types of human ...

Phase I clinical trials remain essential for new drug development, identifying new treatment pathways, and identifying ...

First-line (1L) tislelizumab (TIS) plus chemotherapy (CT) vs placebo (PBO) plus CT in advanced/metastatic esophageal squamous cell carcinoma (ESCC): RATIONALE-306 Japanese subgroup analysis with ...

The global head and neck squamous cell carcinoma market is set for steady growth, driven by advancements in treatment options, increasing awareness of early cancer detection, and rising demand for ...